Leaders in Public Health: Dr. Moupali Das

Join Dean Megan Ranney and Dr. Moupali Das, MD, MPH, a leader in creating HIV breakthroughs, for a fireside chat.

Dr. Das is the Vice President, Clinical Development, HIV Prevention and Virology Pediatrics, at Gilead Sciences and Head, HIV Prevention. Since joining Gilead Sciences, she has leveraged her clinical HIV and infectious disease expertise, clinical trial design and epidemiology skills, and passion for coaching and mentoring to build and lead high-performing cross-functional teams in HIV treatment and prevention.

She has led the PURPOSE program, which is evaluating long-acting lenacapavir for HIV prevention, and HIV Prevention Clinical Development with passion and empathy, revolutionizing how we develop drugs, innovating in the science and health equity, and laying the groundwork for global access. Her research prior to joining Gilead included the development of a novel population-based indicator, community viral load (CVL), to evaluate the impact of treatment as prevention. Her CVL research was the basis for measuring CVL and using viral suppression to evaluate the effectiveness of President Barack Obama’s National HIV/AIDS Strategy.

Drs. Das and Ranney will discuss creating breakthrough science and inclusive clinical trials.

A brief profile of Dr. Das's pre-Gilead career: http://sciencecareers.sciencemag.org/career_magazine/previous_issues/articles/2012_07_13/caredit.a1200079

The Leaders in Public Health Series is open to active Yale community members only for in-person attendance. The general public is welcome and encouraged to participate via the Zoom link provided. Thank you for your understanding.